# high risk relapsed or refractory diffuse large B cell lymphoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/high-risk-relapsed-or-refractory-diffuse-large-b-cell-lymphoma

> No upcoming FDA catalysts in high risk relapsed or refractory diffuse large B cell lymphoma; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for high risk relapsed or refractory diffuse large B cell lymphoma?

No upcoming FDA catalysts in high risk relapsed or refractory diffuse large B cell lymphoma; 3 past events are recorded. SEC Form 8-K: "On March 4, 2026, we issued a press release announced positive topline safety and efficacy results from an investigator initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." [Calendar and source filings](https://sec-api.dev/indications/high-risk-relapsed-or-refractory-diffuse-large-b-cell-lymphoma)

Source: SEC Form 8-K, accession 0001213900-26-023440, https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea0277423-8k_citius.htm (retrieved 2026-11-12). Last confirmed 2026-03-04. Cite: https://sec-api.dev/indications/high-risk-relapsed-or-refractory-diffuse-large-b-cell-lymphoma#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 4, 2026 | [Denileukin topline data readout](https://sec-api.dev/pdufa/denileukin) | CTOR | high risk relapsed or refractory diffuse large B cell lymphoma | completed, positive | "On March 4, 2026, we issued a press release announced positive topline safety and efficacy results from an investigator initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea0277423-8k_citius.htm)) |
| March 4, 2026 | [LYMPHIR (lymphir) topline data readout](https://sec-api.dev/pdufa/lymphir) | CTOR | high risk relapsed or refractory diffuse large B cell lymphoma | completed, positive | "On March 4, 2026, we announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial evaluating LYMPHIR administered prior to commercial CD19 directed" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1851484/000121390026090184/ea0301678-10q_citius.htm)) |
| March 4, 2026 | [Denileukin trial start](https://sec-api.dev/pdufa/denileukin) | CTOR | high risk relapsed or refractory diffuse large B cell lymphoma | completed | "On March 4, 2026, we issued a press release announced positive topline safety and efficacy results from an investigator initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea0277423-8k_citius.htm)) |

## Drugs

- [Denileukin](https://sec-api.dev/pdufa/denileukin) (CTOR)
- [LYMPHIR (lymphir)](https://sec-api.dev/pdufa/lymphir) (CTOR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/high-risk-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "high risk relapsed or refractory diffuse large B cell lymphoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/high-risk-relapsed-or-refractory-diffuse-large-b-cell-lymphoma

```bibtex
@misc{secapidev_indications_high_risk_relapsed_or_refractory_diffuse_large_b_cell_lymphoma_20261116,
  title        = {high risk relapsed or refractory diffuse large B cell lymphoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/high-risk-relapsed-or-refractory-diffuse-large-b-cell-lymphoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_high_risk_relapsed_or_refractory_diffuse_large_b_cell_lymphoma_20261116","title":"high risk relapsed or refractory diffuse large B cell lymphoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/high-risk-relapsed-or-refractory-diffuse-large-b-cell-lymphoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
